NTRK2 and melanoma: We chose to investigate the neurotrophic receptor TRKB (NTRK2), for which three somatic, non-synonymous point mutations have been reported in the studies mentioned above [17], [19], while our own analysis has revealed another TRKB point mutation in a human melanoma cell line.